



Gene Therapy Resource Program

Funded by the National Heart, Lung, and Blood Institute

To access this RSA form, please use one of the following links:

- Approved GTRP investigators - <https://www.gtrp.org/Public/RSA/Default.aspx>
- All other investigators - <https://www.gtrp.org/Public/InvestigatorRegistration/>

Section II - P/T Study Information

Instruction to Submitting Investigator:

* Indicates a required field.

Do not exit your browser without saving your RSA information using one of the save buttons at the bottom of this Section (following item 13)!

If you need to copy information from another RSA, open a new browser window to access that RSA. To navigate between initiated RSAs use the “minimize” and “maximize” buttons. Do not use the forward/back browser buttons.

You may copy and paste text into any text box. After pasting, hit your space bar or add more text – allowing the text box to expand and display all of the information in the text box. You may also edit any information that you have pasted into a text box.

Tables (in Word® or pdf format only) may be uploaded using the RSA Supplement feature. Please direct the reader to this material by referencing the uploaded table within the associated text.

1. Select a study type:

- Pilot Study Pivotal Study (main safety and/or biodistribution study that supports the IND)

2. * Study Title:

3. * Study Abstract:

4. * Rationale for Conducting the Study:

5a. Upload relevant scientific publications/investigator’s brochure/other documents. (5 uploads maximum)

Note: To save and upload a document, select the *Upload* button.

5b. Provide available proof of concept data and if any previous preclinical safety data. (5 uploads maximum)

Note: To save and upload a document, select the *Upload* button.

6. * Select Disease Category:

- Heart Lung Blood Sleep Other

Please specify disease category:

7. Targeted Disease

8. Target organs, tissues, cell, etc.

9. Gene / Vector Name:

10. Animal Model(s) (e.g., knockout mouse, normal pig):

10a. Can the Animal Model be purchased from commercial vendor or other source?

Yes No

Further comment:

10b. Will the Pharm/Tox Core need to induce disease to achieve the above model(s)?

Yes No

Further comment:

11. General Description of Pharmacology/Toxicology/Biodistribution Study Design (doses, route of administration, study endpoint, etc.):

12. Description of the proposed clinical trial:

13. If you have submitted other RSAs that relate to this study, select them from the list below:

2007	Add Remove	
2008		
2009		
2010		
2011		

RSA ID:

Save and Continue

Section III - P/T Regulatory Information

Instruction to Submitting Investigator:

Do not exit your browser without saving your RSA information using one of the save buttons at the bottom of this Section (following item 3)!

If you need to copy information from another RSA, open a new browser window to access that RSA. To navigate between initiated RSAs use the “minimize” and “maximize” buttons. Do not use the forward/back browser buttons.

You may copy and paste text into any text box. After pasting, hit your space bar or add more text – allowing the text box to expand and display all of the information in the text box. You may also edit any information that you have pasted into a text box.

Tables (in Word® or pdf format only) may be uploaded using the RSA Supplement feature. Please direct the reader to this material by referencing the uploaded table within the associated text.

[Section I](#) | [Section II](#) | **[Section III](#)** | [Section IV](#) | [Section V - 1](#) | [Section V - 2](#) | [Section V - 3](#) |

1. Have you discussed pharmacology/toxicology and clinical trial design with the FDA?

Yes No

Meeting Type:

Provide the following information for each contact with FDA:

Contact Date (mm/dd/yyyy): Contact Type: Phone Face-to-Face Email

Meeting/Contact Summary

Upload any FDA communications and other FDA documentation here (3 Uploads Maximum):

Note: To save and upload a document, select the *Upload* button.

To add information about additional meetings/contacts with FDA, please complete the fields above.

2. Reason(s) for requesting Pharmacology/Toxicology testing:

Initial testing required by the FDA?

Yes No

Specific Reason for Request:

Follow-up testing or supplemental testing requested by the FDA?

Yes No

Specific Reason for Request:

Other?

Yes No

Specific Reason for Request:

3. Provide relevant scientific literature and/or guidance documents related to follow-up or supplemental testing requested by the FDA (3 Uploads Maximum).

Browse...

Upload

Note: To save and upload a document, select the *Upload* button.

RSA ID: 2043

Save and Continue

[Return to RSA 2043 Home](#) | [Return to User Main Page](#) | [Return to GTRP Home Page](#) |

Section IV - Study Specific Funding Support

Instructions

Do not exit your browser without saving your RSA information using one of the save buttons at the bottom of this Section!

If you need to copy information from another RSA, open a new browser window to access that RSA. To navigate between initiated RSAs use the "minimize" and "maximize" buttons. **Do not** use the forward/back browser buttons.

[Section I](#) | [Section II](#) | [Section III](#) | **[Section IV](#)** | [Section V - 1](#) | [Section V - 2](#) | [Section V - 3](#) |

Please provide information on your current and pending funding for this research study.

NHLBI Funding

Other NIH Funding

Other Funding (Institutional, Foundation, Industry, etc.)

No Funding Secured

RSA ID: 2043

Save and Continue

[Return to RSA 2043 Home](#) | [Return to User Main Page](#) | [Return to GTRP Home Page](#) |

Section V-1 - Vector Information

Instruction to Submitting Investigator:

Do not exit your browser without saving your RSA information using one of the save buttons at the bottom of this Section (following item 12)!

If you need to copy information from another RSA, open a new browser window to access that RSA. To navigate between initiated RSAs use the “minimize” and “maximize” buttons. Do not use the forward/back browser buttons.

You may copy and paste text into any text box. After pasting, hit your space bar or add more text – allowing the text box to expand and display all of the information in the text box. You may also edit any information that you have pasted into a text box.

Tables (in Word® or pdf format only) may be uploaded using the RSA Supplement feature. Please direct the reader to this material by referencing the uploaded table within the associated text.

Note to Investigator: Please contact the Pharm/Tox Core regarding the amount of vector needed and the preferred vialing.

[Section I](#) | [Section II](#) | [Section III](#) | [Section IV](#) | **[Section V - 1](#)** | [Section V - 2](#) | [Section V - 3](#)

1. Has the test material been made?

Yes No

1a. When will it be available?

Comments:

2. Gene/Vector Name:

3. Vector Source (who is producing vector):

4. Estimated amount of material to be provided (total particles/vector genomes or transduction):

5. Vector Grade:

Note to Investigator: GMP process-comparable indicates vector prepared using similar cell culture and purification processes as GMP material, but for which some GMP requirements (such as raw materials qualification, manufacturing facility environmental monitoring, and in-process monitoring of process intermediates) are not fully implemented. In addition, characterization and release testing of this material is less extensive than for full GMP-grade material.

6. If available, provide relevant information for the vector regarding:

6a. Titer (physical and infectious):

6b. Intended characterization (e.g., identity, purity, potency):

6c. Vehicles and Excipients (indicate Lovelace to purchase or provided by vector lab):

6d. Storage conditions required:

6e. Stability; shelf life under intended storage conditions:

6f. Stability under conditions of use:

6g. Vialing: concentration of vector and volume per vial (please discuss with Lovelace for vialing appropriate for the study):

6h. Special handling procedures:

Upload special handling procedures document here (if any): (5 uploads maximum)

Note: To save and upload a document, select the *Upload* button.

6i. Known toxicities (in vitro or in vivo) with transgene expression and/or vector:

Upload known toxicities here (if any): (5 uploads maximum)

Note: To save and upload a document, select the *Upload* button.

7. Describe method used to make vector:

8. Vector Construct:

8a. Vector Type:

8b. Serotype:

8c. Transgene:

8d. Promoter:

8e. Transgene species specificity (e.g., human, mouse, etc.):

8f. Packaging cell line:

Upload sequence data here:

Note: To save and upload a document, select the **upload** button.(1 upload maximum)

Upload gene vector map here:

Note: To save and upload a document, select the **upload** button.(1 upload maximum)

9. Briefly describe the strategy used in construction of the vector and reasons for including viral sequences, the specific transgene sequences, and any enhancer/promoter or other regulatory regions.

10. What is the tissue specificity of the transgene expression, if any?

11. Does the investigator have an assay/method for quantifying vector?

Yes No

Will the Investigator develop an assay?

Yes No

Will Lovelace need to develop an assay?

Yes No

12. If assessment of gene expression by qPCR is an endpoint for this study, does the investigator have an assay in place?

Yes No

RSA ID: 2043

Save and Continue

Section V-2 - Animal Model: Testing Information Requested

Instruction to Submitting Investigator:

Do not exit your browser without saving your RSA information using one of the save buttons at the bottom of this Section (following item 3)!

If you need to copy information from another RSA, open a new browser window to access that RSA. To navigate between initiated RSAs use the “minimize” and “maximize” buttons. Do not use the forward/back browser buttons.

You may copy and paste text into any text box. After pasting, hit your space bar or add more text – allowing the text box to expand and display all of the information in the text box. You may also edit any information that you have pasted into a text box.

Tables (in Word® or pdf format only) may be uploaded using the RSA Supplement feature. Please direct the reader to this material by referencing the uploaded table within the associated text.

Note to Investigator: In this section you will need to provide the following information:

- Required animal models
- Details for each animal model
- Tests/Assays for each animal model

[Section I](#) | [Section II](#) | [Section III](#) | [Section IV](#) | [Section V - 1](#) | **[Section V - 2](#)** | [Section V - 3](#)

***Animal model(s)**

Please only select one model at a time. You will have a chance to "Select Another Animal Model" at the end.

Mouse

***a. Age of animals to be used:** (Check all that apply)

Neonates Young adults Sexually mature Retired breeders

Neonates Information

b-1. Further description of animal model (Check all that apply)

Strain
 Genetically-modified or knockout model
 Disease model name

b-2. Tests/Assays

Hematology
 Serum Chemistry
 Coagulation Parameters
 Pharmacokinetics/Biodistribution of Vector (Quantitative real time PCR)
 Histopathology
 Transgene expression
 Antibodies to vector and/or transgene
 Cell-mediated immunity to vector and/or transgene
 Biomarkers of Gene Function
 Other

b-3. Route of Administration

If unique delivery method, can you transfer dosing methods to the Pharm/Tox Core?

Yes No TBD

Further comment

If necessary, can you come to the Pharm/Tox Core to dose?

Yes No TBD

Further comment

Will specialized equipment (e.g., fluoroscope, ultrasound, i-Stat) be needed for dosing?

Yes No

Further comment

What device(s) (e.g., inhalation system, catheter, electroporation device) will be involved in the administration/delivery?

Further comment

Will any of the devices require FDA review?

Yes No TBD

Further comment

RSA ID: 2043

Save And Select Another Animal Model

Save and Continue

Section V-3 - Laboratories and Timelines: Testing Requested Information

Instruction to Submitting Investigator:

Do not exit your browser without saving your RSA information using one of the save buttons at the bottom of this Section (following item 2)!

If you need to copy information from another RSA, open a new browser window to access that RSA. To navigate between initiated RSAs use the “minimize” and “maximize” buttons. Do not use the forward/back browser buttons.

You may copy and paste text into any text box. After pasting, hit your space bar or add more text – allowing the text box to expand and display all of the information in the text box. You may also edit any information that you have pasted into a text box.

Tables (in Word® or pdf format only) may be uploaded using the RSA Supplement feature. Please direct the reader to this material by referencing the uploaded table within the associated text.

[Section I](#) | [Section II](#) | [Section III](#) | [Section IV](#) | [Section V - 1](#) | [Section V - 2](#) | [Section V - 3](#) |

1. Will a laboratory other than the Pharm/Tox Core perform a portion or all of the preclinical animal safety/biodistribution work?

Yes No

Please provide the laboratory name and location

2. Testing Timelines

Describe any timeline constraints regarding any testing.

RSA ID: 2043

Submit Final RSA

[Return to RSA 2043 Home](#) | [Return to User Main Page](#) | [Return to GTRP Home Page](#) |